Participation Tools: Individual Quality Measures for 2010 PQRI
The 129 individual quality measures eligible for claims-based reporting in the 2010 PQRI program are listed below. The measures are sorted alphabetically by disease/condition. For each measure that you feel might be applicable to your practice, view any of the three PDF documents.
These participation tools are intended for claims-based reporting of individual measures.
Participation Tools disclaimer
These participation tools include measures and specifications ("Participation Tools"). The American Medical Association, the Physician Consortium for Performance Improvement®, its members and other measure and specifications developers ("Measure Developers") do not warrant that the information contained in the Participation Tools is in every respect accurate and/or complete. The Measure Developers assume no responsibility for use of the information contained in the Participation Tools. The Measure Developers assume no responsibility for and expressly disclaim liability for damages of any kind arising out of the use of, reference to, or reliance on the content of the Participation Tools.
Participation tools for Measures Groups are also available: View the 2010 PQRI Measures Group Tools.
Many of the measures in the PQRI were developed by the AMA-convened Physician Consortium for Performance Improvement® (PCPI), in collaboration with the National Committee for Quality Assurance (NCQA) and/or a medical specialty society. For additional information on the PCPI including additional background information on the quality measures with both the rationale and evidence base for each measure, please visit the PCPI Web page.
Questions:
For additional information on the PQRI program, please visit the CMS Web site.
For questions or comments on the participation tools, please contact cpe@ama-assn.org
#166
#116. Antibiotic treatment for adults with acute bronchitis - avoidance of inappropriate use
#28. Aspirin at arrival for acute myocardial infarction (AMI)
#91. Topical therapy
#92. Pain assessment
#93. Systemic antimicrobial therapy – avoidance of inappropriate use
#193. Perioperative temperature management
#53. Pharmacologic therapy
#64. Asthma assessment
#156. Radiation dose limits to normal tissues
#194. Cancer stage documented
Breast Cancer
#71. Hormonal therapy for stage IC-III, ER/PR positive breast cancer
Chronic Lymphocytic Leukemia#70. Baseline flow cytometry
Colon Cancer
#72. Chemotherapy for stage III colon cancer patients
Multiple Myeloma
#69. Treatment with bisphosphonates
Myelodysplastic Syndrome
#68. Documentation of iron stores in patients receiving erythropoietin therapy
Myelodysplastic Syndrome & Acute Leukemias
#67. Baseline cytogenetic testing performed on bone marrow
Prostate Cancer
#102. Avoidance of overuse of bone scan for staging low-risk prostate cancer patients
#104. Adjuvant hormonal therapy for high-risk prostate cancer patients
#105. Three-dimensional radiotherapy
#54. 12-Lead electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain
#182. Functional outcome assessment in chiropractic care
#121. Laboratory testing (calcium, phosphorus, intact parathyroid hormone (iPTH) and lipid profile)
#122. Blood pressure management
#123. Plan of care - elevated hemoglobin for patients receiving erythropoiesis-stimulating agents (ESA)
#135. Influenza Immunization
#153. Referral for arteriovenous (AV) fistula
#51. Spirometry evaluation
#52. Bronchodilator therapy
#186. Use of compression system in patients with venous ulcers
#56. Vital signs
#57. Assessment of oxygen saturation
#58. Assessment of mental status
#59. Empiric antibiotic
#43. Use of internal mammary artery (IMA) in patients with isolated CABG surgery
#44. Preoperative beta-blocker in patients with isolated CABG surgery
#06. Oral antiplatelet therapy prescribed for patients with coronary artery disease
#76. Prevention of catheter-related bloodstream infections (CRBSI) – central venous catheter insertion protocol
#09. Antidepressant medication during acute phase for patients with major depressive disorder
#106. Diagnostic evaluation
#107. Suicide risk assessment
#01. Hemoglobin A1c poor control in diabetes mellitus
#02. Low density lipoprotein cholesterol control in diabetes mellitus
#03. High blood pressure control in diabetes mellitus
#117. Dilated eye exam in diabetic patient
#119. Urine screening for microalbumin or medical attention for nephropathy in diabetic patients
#126. Diabetic foot and ankle care, peripheral neuropathy: neurological evaluation#127. Diabetic foot and ankle care, ulcer prevention: evaluation of footwear
#163. Foot exam#188. Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear
#189. Referral for Otologic Evaluation for Patients with a History of Active Drainage From the Ear Within the Previous 90 Days
#190. Referral for Otologic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss
#79. Influenza immunization
#185. Colonoscopy interval for patients with a history of adenomatous polyps – Avoidance of inappropriate use
Age-Related Macular Degeneration
#14. Dilated macular examination
#140. Counseling on antioxidant supplement
Cataracts
#139. Comprehensive preoperative assessment for cataract surgery with intraocular lens (IOL) placement
Diabetic Retinopathy
#18. Documentation of presence or absence of macular edema and level of severity of retinopathy
#19. Communication with the physician managing ongoing diabetes care
Primary Open Angle Glaucoma
#12. Optic nerve evaluation
#141. Reduction of intraocular pressure (IOP) by 15% OR documentation of a plan of care
#46. Medication reconciliation: Reconciliation after discharge from an inpatient facility
#47. Advance care plan
#181. Elder maltreatment screen and follow-up plan
Falls
#154. Risk assessment
#155. Plan of care
#124. Adoption/use of electronic health records (EHR)
#84 . Ribonucleic acid (RNA) testing before initiating treatment
#85. HCV genotype testing prior to treatment
#86. Antiviral treatment prescribed
#87. HCV Ribonucleic acid (RNA) testing at week 12 of treatment
#89. Counseling regarding risk of alcohol consumption
#90. Counseling regarding use of contraception prior to antiviral therapy
#183. Hepatitis A vaccination in patients with HCV
#184. Hepatitis B vaccination in patients with HCV
#201. Blood pressure management control
#202. Complete lipid profile
#203. Low density lipoprotein (LDL-C) control
#204. Use of aspirin or another antithrombotic
#130. Documentation and verification of current medications in the medical record
#147. Correlation with existing imaging studies for all patients undergoing bone scintigraphy
#109. Function and pain assessment
#142. Assessment for use of anti-inflammatory or analgesic over-the-counter (OTC) medications
#24. Communication with the physician managing ongoing care post-fracture
#39. Screening or therapy for osteoporosis for women aged 65 years and older
#40. Management following fracture
#41. Pharmacologic therapy
#94. Diagnostic evaluation – assessment of tympanic membrane mobility
#99 . Breast cancer resection pathology reporting: pT category (primary tumor) and pN category (regional lymph nodes) with histologic grade
#100. Colorectal cancer resection pathology reporting: pT category (primary tumor) and pN category (regional lymph nodes) with histologic grade
#131. Pain assessment prior to initiation of patient therapy and follow-up
#175. Influenza immunization
#20. Timing of antibiotic prophylaxis - Ordering physician
#21. Selection of prophylactic antibiotic - First OR second generation cephalosporin
#22. Discontinuation of prophylactic antibiotics (Non-cardiac procedures)
#23. Venous thromboembolism (VTE) prophylaxis (When indicated in ALL patients)
#30. Timing of prophylactic antibiotics - Administering physician
#45. Discontinuation of prophylactic antibiotics (Cardiac procedures)
#157. Recording of clinical stage for lung cancer and esophageal cancer resection
#158. Use of patch during conventional endarterectomy
# 172. Hemodialysis vascular access decision-making by surgeon to maximize placement of autogenous arterial venous (AV) fistula
#66. Appropriate testing for children with pharyngitis
#110. Influenza immunization for patients ≥ 50 years old
#111. Pneumonia vaccination for patients 65 years and older
#112. Screening mammography
#113. Colorectal cancer screening
#114. Inquiry regarding tobacco use
#115. Advising smokers to quit
#128. Body mass index (BMI) screening and follow-up
#134. Screening for clinical depression and follow-up plan
#173. Unhealthy alcohol use - screening
#10. Computed tomography (CT) or magnetic resonance imaging (MRI) reports
#145. Exposure time reported for procedures using fluoroscopy#146. Inappropriate use of "probably benign" assessment category in mammography screening
#195. Stenosis measurement in carotid imaging reports
#108. Disease modifying anti-rheumatic drug (DMARD) therapy
#176. Tuberculosis screening
#177. Periodic assessment of disease activity
#178. Functional status assessment
#179. Assessment and classification of disease prognosis
#180. Glucocorticoid management
#31. Deep vein thrombosis (DVT) prophylaxis for ischemic stroke or intracranial hemorrhage
#32. Discharged on antiplatelet therapy
#35. Screening for dysphagia#36. Consideration of rehabilitation services
#55. 12 Lead electrocardiogram performed for syncope
#65. Treatment for children with upper respiratory infection - avoidance of inappropriate use
#48. Assessment of presence or absence of urinary incontinence in women aged 65 years and older
#49. Characterization of urinary incontinence in women aged 65 years and older
#50. Plan of care for urinary incontinence in women aged 65 years and older
